Abstract
A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon-beta 1a potently inhibits SARS coronavirus replication in vitro.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antiviral Agents / pharmacology*
-
Chlorocebus aethiops
-
Cytopathogenic Effect, Viral / drug effects
-
Humans
-
In Vitro Techniques
-
Interferon Type I / pharmacology
-
Interferon beta-1a
-
Interferon-beta / pharmacology*
-
Recombinant Proteins
-
Severe Acute Respiratory Syndrome / drug therapy
-
Severe Acute Respiratory Syndrome / epidemiology
-
Severe Acute Respiratory Syndrome / virology
-
Severe acute respiratory syndrome-related coronavirus / drug effects*
-
Severe acute respiratory syndrome-related coronavirus / physiology*
-
Vero Cells
-
Virus Replication / drug effects*
Substances
-
Antiviral Agents
-
Interferon Type I
-
Recombinant Proteins
-
Interferon-beta
-
Interferon beta-1a